Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.

Breuer J, Gutierrez J, Latchaw R, Lehr R, Sorensen AG.

J Magn Reson Imaging. 2014 Feb;39(2):410-8. doi: 10.1002/jmri.24180. Epub 2013 May 16.

PMID:
23681501
2.

Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.

Katakami N, Inaba Y, Sugata S, Tsurusaki M, Itoh T, Machida T, Tanaka H, Nakayama T, Morikawa T, Breuer J, Aitoku Y.

Invest Radiol. 2011 Jul;46(7):411-8. doi: 10.1097/RLI.0b013e3182145a6c.

PMID:
21467949
3.

Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.

Gutierrez JE, Rosenberg M, Duhaney M, Simon JA, Brueggenwerth G, Agris JM, Knopp EA.

J Magn Reson Imaging. 2015 Mar;41(3):788-96. doi: 10.1002/jmri.24583. Epub 2014 Feb 27.

PMID:
24578298
4.

A multicenter, randomized, controlled, single-blind comparison phase III study to determine the efficacy and safety of gadobutrol 1.0 M versus gadopentetate dimeglumine following single injection in patients referred for contrast-enhanced MRI of the body regions or extremities.

Kuwatsuru R, Takahashi S, Umeoka S, Sugihara R, Zeng M, Huan Y, Peng W, Ma L, Guo L, Teng G, Yao W, Tozaki M, Endo M, Kaji S, Ro T, Tae Hahn S, Chul Kang B, Nishimura H, Sugawara Y, Katakami N, Breuer J, Aitoku Y.

J Magn Reson Imaging. 2015 Feb;41(2):404-13. doi: 10.1002/jmri.24566. Epub 2014 Apr 1.

PMID:
24692302
5.

A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System.

Tanaka A, Masumoto T, Yamada H, Kurauchi M, Breuer J.

Magn Reson Med Sci. 2016;15(2):227-36. doi: 10.2463/mrms.mp.2015-0083. Epub 2015 Dec 21.

6.

Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.

Anzalone N, Scarabino T, Venturi C, Cristaudo C, Tartaro A, Scotti G, Zimatore D, Floris R, Carriero A, Longo M, Cirillo M, Cova MA, Gatti S, Voth M, Colosimo C.

Eur J Radiol. 2013 Jan;82(1):139-45. doi: 10.1016/j.ejrad.2011.07.005. Epub 2011 Sep 3.

PMID:
21890295
7.

Safety and Efficacy of Gadobutrol for Contrast-enhanced Magnetic Resonance Imaging of the Central Nervous System: Results from a Multicenter, Double-blind, Randomized, Comparator Study.

Gutierrez JE, Rosenberg M, Seemann J, Breuer J, Haverstock D, Agris J, Balzer T, Anzalone N.

Magn Reson Insights. 2015 Apr 7;8:1-10. doi: 10.4137/MRI.S19794. eCollection 2015 Apr 7. Erratum in: Magn Reson Insights. 2015;8:23.

8.

Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.

Hammerstingl R, Adam G, Ayuso JR, Van Beers B, Belfiore G, Bellin MF, Bongartz G, Ernst O, Frericks B, Giuseppetti G, Heinz-Peer G, Laghi A, Martin J, Pering C, Reimer P, Richter GM, Roemer FW, Schäfer FK, Vilgrain V, Vogl TJ, Weishaupt D, Wall A, Zech CJ, Tombach B.

Invest Radiol. 2009 Mar;44(3):168-76. doi: 10.1097/RLI.0b013e318198a0ae.

PMID:
19169143
9.

Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Seidl Z, Vymazal J, Mechl M, Goyal M, Herman M, Colosimo C, Pasowicz M, Yeung R, Paraniak-Gieszczyk B, Yemen B, Anzalone N, Citterio A, Schneider G, Bastianello S, Ruscalleda J.

AJNR Am J Neuroradiol. 2012 Jun;33(6):1050-8. doi: 10.3174/ajnr.A3033. Epub 2012 Mar 1.

10.

[Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study].

Vogl TJ, Friebe CE, Balzer T, Mack MG, Steiner S, Schedel H, Pegios W, Lanksch W, Banzer D, Felix R.

Radiologe. 1995 Aug;35(8):508-16. German.

PMID:
7568795
11.

Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study).

Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Žižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G.

AJNR Am J Neuroradiol. 2015 Jan;36(1):14-23. doi: 10.3174/ajnr.A4154. Epub 2014 Oct 9.

12.

A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.

Runge VM, Armstrong MR, Barr RG, Berger BL, Czervionke LF, Gonzalez CF, Halford HH, Kanal E, Kuhn MJ, Levin JM, Low RN, Tanenbaum LN, Wang AM, Wong W, Yuh WT, Zoarski GH.

Invest Radiol. 2001 Feb;36(2):65-71.

PMID:
11224753
13.
14.

Brain MRI with single-dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: comparison with 0.15 mmol/kg Gadoterate meglumine.

Kramer H, Runge VM, Naul LG, Loynachan AT, Reiser MF, Wintersperger BJ.

AJR Am J Roentgenol. 2010 May;194(5):1337-42. doi: 10.2214/AJR.09.3427.

PMID:
20410423
15.

Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T.

Morelli JN, Runge VM, Vu L, Loynachan AT, Attenberger UI.

Invest Radiol. 2010 Dec;45(12):810-8. doi: 10.1097/RLI.0b013e3181f03d8a.

PMID:
20856127
16.

Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial.

Tombach B, Bohndorf K, Brodtrager W, Claussen CD, Düber C, Galanski M, Grabbe E, Gortenuti G, Kuhn M, Gross-Fengels W, Hammerstingl R, Happel B, Heinz-Peer G, Jung G, Kittner T, Lagalla R, Lengsfeld P, Loose R, Oyen RH, Pavlica P, Pering C, Pozzi-Mucelli R, Persigehl T, Reimer P, Renken NS, Richter GM, Rummeny EJ, Schäfer F, Szczerbo-Trojanowska M, Urbanik A, Vogl TJ, Hajek P.

Eur Radiol. 2008 Nov;18(11):2610-9. doi: 10.1007/s00330-008-1054-2. Epub 2008 Jul 8.

PMID:
18607594
17.

Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.

Knopp MV, Bourne MW, Sardanelli F, Wasser MN, Bonomo L, Boetes C, Müller-Schimpfle M, Hall-Craggs MA, Hamm B, Orlacchio A, Bartolozzi C, Kessler M, Fischer U, Schneider G, Oudkerk M, Teh WL, Gehl HB, Salerio I, Pirovano G, La Noce A, Kirchin MA, Spinazzi A.

AJR Am J Roentgenol. 2003 Sep;181(3):663-76.

PMID:
12933457
18.

Effect of imaging time in the magnetic resonance detection of intracerebral metastases using single dose gadobutrol.

Jeon JY, Choi JW, Roh HG, Moon WJ.

Korean J Radiol. 2014 Jan-Feb;15(1):145-50. doi: 10.3348/kjr.2014.15.1.145. Epub 2014 Jan 8.

19.
20.

The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients.

Lowe LH, Kearns GL, Wible JH Jr.

Curr Med Res Opin. 2006 Dec;22(12):2515-24.

PMID:
17166334

Supplemental Content

Support Center